Xalatan, Latanoprost

Xalatan, Latanoprost Newswire

Comprehensive Real-Time News Feed for Xalatan, Latanoprost (generic).

Results 1 - 20 of 35 in Xalatan, Latanoprost (generic)

  1. Comparison of the effects of bimatoprost and a fixed combination of...Read the original story

    Thursday Jan 22 | BioMed Central

    To compare the effect of bimatoprost and the fixed combination latanoprost-timolol on 24-hour systolic and diastolic blood pressure and on 24-hour ocular perfusion pressure . 200 patients with glaucoma or ocular hypertension, controlled on the unfixed combination of latanoprost and timolol or eligible for dual therapy being not being fully controlled on monotherapy were enrolled in a randomized, double-masked, placebo-controlled, multicentre clinical trial.

    Comment?

  2. Reply to: 'Glaucoma prescribing trends in England 2000 to 2012'Read the original story

    Wednesday Jan 7 | Eye

    In May 2013, we performed a prospective audit in our unit to assess current prescribing trends in our glaucoma clinics. Our results are consistent with national trends.

    Comment?

  3. Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic PharmaceuticalRead the original story w/Photo

    Dec 23, 2014 | Seeking Alpha

    Aerie is a development stage biotech with no approved products, thus it is essentially a binary investment: zero or offering significant upside. If Rhopressa Phase 3 results match the previous Phase 2 results, Aerie will have the 2nd most effective drug class for reducing intraocular pressures .

    Comment?

  4. Market Report, "PH&T S.p.a. - Pharmaceuticals & Healthcare - Deals and Alliances Profile", publishedRead the original story

    Dec 23, 2014 | PR-inside.com

    The company researches, develops and produces generic drugs for specialist therapies and medical devices. Its products include alfuzosin, amiodarone, budesonide, calcitriol, desmopressin, donepezil, dorzolamide and timolol, epoprostenol, exemestane, flutamide, glyceryl trinitrate, latanoprost and latanoprost.

    Comment?

  5. Prostaglandin analogue eye drops reduce risk of vision loss in OAG patientsRead the original story w/Photo

    Dec 21, 2014 | Medical News

    Prostaglandin analogue eye drops, the most commonly prescribed treatment for glaucoma, can greatly reduce risk of vision loss in people with open angle glaucoma , one of the leading causes of blindness, according to the first placebo-controlled trial to assess their vision-preserving effect published in The Lancet . "Medication to lower raised eye pressure has been used for decades as the main treatment for OAG to delay progressive vision loss.

    Comment?

  6. Study Supports Benefit of Widely Used Glaucoma DrugRead the original story w/Photo

    Dec 19, 2014 | MedicineNet

    Prostaglandin analogue eye drops -- a common form of glaucoma drug -- significantly reduce the risk of vision loss in patients with the eye disease, a new study finds. British researchers led by David Garway-Heath, of the Moorfields Eye Hospital and UCL Institute of Ophthalmology in London, tracked outcomes for more than 500 people newly diagnosed with open-angle glaucoma -- the most common form of the disease and one of the leading causes of blindness .

    Comment?

  7. Most commonly prescribed glaucoma drug reduces risk of vision loss by more than 50% over 2 yearsRead the original story w/Photo

    Dec 18, 2014 | Science Daily

    "Medication to lower raised eye pressure has been used for decades as the main treatment for OAG to delay progressive vision loss. But, until now, the extent to which the most frequently prescribed class of pressure-lowering drugs have a protective effect on vision was not known," explains the lead author of a new study.

    Comment?

  8. Most Commonly Prescribed Glaucoma Drug Reduces Risk Of Vision Loss By ...Read the original story

    Dec 18, 2014 | BioSpace

    The Lancet: Most Commonly Prescribed Glaucoma Drug Reduces Risk Of Vision Loss By More Than 50% Over 2 Years "Medication to lower raised eye pressure has been used for decades as the main treatment for OAG to delay progressive vision loss. But, until now, the extent to which the most frequently prescribed class of pressure-lowering drugs have a protective effect on vision was not known" *, explains David Garway-Heath, lead author and International Glaucoma Association Professor of Ophthalmology at the NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK.

    Comment?

  9. Latanoprost Preserves Vision in Open-Angle GlaucomaRead the original story

    Dec 18, 2014 | Journal Watch

    Latanoprost helps maintain visual field function in patients with open-angle glaucoma, according to an industry-supported study in the Lancet . Latanoprost is a prostaglandin analogue frequently used to lower intraocular pressure in glaucoma.

    Comment?

  10. Aerie Pharmaceuticals Added to NASDAQ Biotechnology IndexRead the original story

    Dec 16, 2014 | Customer Interaction Solutions

    Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that it has been selected for addition to the NASDAQ Biotechnology Index , which will become effective upon market open on Monday, December 22, 2014. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark.

    Comment?

  11. Spin Doctors; Data And Market Projections From Aerie Pharmaceuticals, Inc. Are Too OptimisticRead the original story w/Photo

    Dec 12, 2014 | Seeking Alpha

    Aerie's P3 registration trials for their Glaucoma treatment, Rhopressa, are based on early clinical trial success and a clear medical need for better drugs. In their public presentations they claim that the new treatment is superior to existing 'standard of care' although the data they show makes it not-quite-as-good as the generics.

    Comment?

  12. Indian stock market and companies daily reportRead the original story

    Dec 2, 2014 | Stock Market Review

    Indian markets are expected to open on a flat note tracking the SGX Nifty. U.S. stocks rose to record highs led by biotechnology and energy companies and data on construction spending boosted confidence in the economy.

    Comment?

  13. Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results...Read the original story w/Photo

    Sep 30, 2014 | Business Wire

    BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.-- --Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for third quarter 2014 and provided an update on the Company's business highlights. RoclatanTM Phase 3 enabling activities also are ongoing, and Phase 3 registration trials are expected to commence in mid-2015.

    Comment?

  14. Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial...Read the original story w/Photo

    Oct 28, 2014 | Business Wire

    BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.-- --Aerie Pharmaceuticals, Inc. announced today that its third quarter 2014 financial results will be released after the market closes on Tuesday, November 11, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.

    Comment?

  15. Research and Markets: Global Glaucoma Treatment Market: Trends and Opportunities 2014-2019Read the original story w/Photo

    Oct 15, 2014 | Business Wire

    This report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market.

    Comment?

  16. BioLight Israeli: A Small-Cap Biotech With Potential UpsideRead the original story w/Photo

    Oct 1, 2014 | Seeking Alpha

    IOPtiMate, laser surgical device for glaucoma and CellDetectA cell staining technology for detecting and monitoring cancer cells, had a soft launch at the beginning of this year. BioLight Life Sciences Investments Ltd. invests in, manages and commercializes biomedical innovations grouped around defined medical conditions.

    Comment?

  17. Aerie Announces Closing of $125 Million Convertible Notes FinancingRead the original story w/Photo

    Sep 30, 2014 | Business Wire

    BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.-- -- Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. , a current Aerie shareholder. Under the terms of the financing, the notes are secured and will accrue interest at a rate of 1.75% per annum until maturity in September of 2021.

    Comment?

  18. Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) - Daedal ResearchRead the original story

    Sep 30, 2014 | PR Log

    The report titled "Global Glaucoma Treatment Market: Trends and Opportunities " provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. PRLog - Sep. 30, 2014 - DELHI, India -- The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector.

    Comment?

  19. Can Valeant's Glaucoma Drug Peak Sales Be Much Lower Than Claimed?Read the original story w/Photo

    Sep 26, 2014 | Seeking Alpha

    Valeant's Phase 3 trial results compared its latanoprostene bunod with the generic timolol. There is no proof it is better than the market-leading prostaglandin analogs because it wasn't compared.

    Comment?

  20. Aerie Announces $125 Million Convertible NotesRead the original story

    Sep 9, 2014 | Freshnews

    BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. -- -- Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has received a $125 million financing commitment from Deerfield Management Company L.P. , a current Aerie shareholder.

    Comment?